Multiple Sclerosis (MS) Clinical Trial
Official title:
A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis
The study is divided into a Core Part and Extension Part. The Core Part is a 24-month, double-blind, triple dummy, randomized, 3-arm active-controlled in children/adolescent patients aged 10-17 years old with Multiple Sclerosis (MS). The Extension Part is 60-month (5 year) open label (except for first 12 weeks transition which will remain double-blind) treatment for patients who complete the Core Part of the study and meet all inclusion/exclusion criteria. The targeted enrollment is 120 participants with multiple sclerosis which will include at least 5 participants with body weight (BW) ≤40 kg and at least 5 participants with age 10 to 12 years in each of the ofatumumab and siponimod arms. There is a minimum 6 month follow up period for all participants (core and extension). Total duration of the study could be up to 7 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05177523 -
Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis
|
||
| Not yet recruiting |
NCT06053749 -
An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
|
||
| Not yet recruiting |
NCT06450600 -
Enhancing Quality of Life in MS Patients Through Tailored Therapeutic Education
|
N/A | |
| Not yet recruiting |
NCT03624296 -
Characterization of Cortical Injury in Early MS Patients: a 7T MRI Study
|
N/A | |
| Terminated |
NCT04203498 -
Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis
|
Phase 3 | |
| Active, not recruiting |
NCT04602390 -
Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis
|
Phase 1 | |
| Completed |
NCT01804647 -
Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease
|
||
| Terminated |
NCT04907305 -
Next-Gen MS: Feed-forward PRO Data for MS Research
|
||
| Active, not recruiting |
NCT03456206 -
Chronic Inflammatory Disease, Lifestyle and Risk of Disease
|
||
| Completed |
NCT04705610 -
Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography
|
N/A | |
| Completed |
NCT01366027 -
PRISM Registry: Pseudobulbar Affect Registry Series
|
N/A | |
| Completed |
NCT03135249 -
Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis
|
Phase 4 | |
| Recruiting |
NCT05633875 -
Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis
|
||
| Completed |
NCT02612935 -
An Observational Pilot Study of Lumosity Computerized Cognitive Training in Subjects With Multiple Sclerosis
|
N/A | |
| Completed |
NCT02739542 -
Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)
|
Phase 4 | |
| Completed |
NCT03177655 -
Effect of Guided Imagery on Well-being in Patients With Multiple Sclerosis
|
N/A | |
| Active, not recruiting |
NCT04777539 -
Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis
|
||
| Recruiting |
NCT02352194 -
Physical Capacity and Rehabilitation of Patients With Multiple Sclerosis
|
N/A | |
| Completed |
NCT02308579 -
Centralized Reading Assessment of Chronic CerebroSpinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis and Other Neurological Diseases
|
N/A | |
| Withdrawn |
NCT01710228 -
Alternative Treatment Paradigm for Natalizumab Trial
|
Phase 2 |